Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

被引：0
|
作者：
Moshe C. Ornstein
Laura S. Wood
机构：
[1] Cleveland Clinic,Hematology and Medical Oncology
[2] Cleveland Clinic,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adverse event; Axitinib; Combination; First-line; Immune checkpoint inhibitor; Renal cell carcinoma; Therapy management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3599 / 3609
页数：10
相关论文
共 50 条
  • [11] Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib plus checkpoint inhibitor (CPI) therapy
    Huynh, L.
    Du, S. S.
    Chang, R.
    Pi, S.
    Sundaresan, S.
    Duh, M. S.
    Thomaidou, D.
    Zanotti, G.
    Zakharia, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1404 - S1405
  • [12] Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
    Sharma, Rohini
    Aval, Leila Motedayen
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [13] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [14] CLINICAL OUTCOMES OF AXITINIB VERSUS SUNITINIB AS A FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN JAPANESE PATIENTS
    Kiso, Yusuke
    Inoue, Takamitsu
    Nara, Taketoshi
    Kanda, Sohei
    Numakura, Kazuyuki
    Tsuruta, Hiroshi
    Saito, Mitsuru
    Narita, Shintaro
    Satoh, Shigeru
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2018, 199 (04): : E874 - E874
  • [15] First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
    Kazuyuki Numakura
    Mizuki Kobayashi
    Yumina Muto
    Yuya Sekine
    Makoto Takahashi
    Soki Kashima
    Ryohei Yamamoto
    Atsushi Koizumi
    Taketoshi Nara
    Mitsuru Saito
    Shintaro Narita
    Hiroshi Nanjyo
    Tomonori Habuchi
    Scientific Reports, 10
  • [16] First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
    Numakura, Kazuyuki
    Kobayashi, Mizuki
    Muto, Yumina
    Sekine, Yuya
    Takahashi, Makoto
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Nanjyo, Hiroshi
    Habuchi, Tomonori
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [17] Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)
    Jonasch, E.
    Bair, A.
    Chen, Y.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [18] A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
    Jo, Hyunji
    Hong, Joohyun
    Kim, Hongsik
    Kim, Hye Ryeon
    Kwon, Ghee Young
    Kang, Kyung A.
    Park, Sung Yoon
    Kim, Chan Kyo
    Park, Byung Kwan
    Chung, Jae Hoon
    Song, Wan
    Kang, Minyong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Park, Se Hoon
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [19] First-line therapy for metastatic renal cell carcinoma
    Sawhney, Paramvir
    Suyanto, Suyanto
    Michael, Agnieszka
    Pandha, Hardev
    JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
  • [20] Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
    Graham, Jeffrey
    Wells, John Connor
    Dudani, Shaan
    Gan, Chun L.
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Meza, Luis
    Beuselinck, Benoit
    Hansen, Aaron
    North, Scott A.
    Bjarnason, Georg A.
    Sayegh, Nicolas
    Kanesvaran, Ravindran
    Wood, Lori A.
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 124 - 132
12345